title: Analysis of topoisomerase mutations in fluoroquinolone-resistant and -susceptible Campylobacter jejuni strains isolated in Senegal.
abstract: In this study, topoisomerase mutations in ciprofloxacin-resistant and -susceptible Campylobacter jejuni were analysed by DNA sequencing. In certain ciprofloxacin-resistant C. jejuni, the mechanism of resistance was complex. The Thr86-Ala substitution in the GyrA protein appears to play a role in increasing the minimum inhibitory concentration of nalidixic acid only. In addition, isolates with this amino acid change and those resistant to quinolones but lacking a mutation in the GyrA quinolone resistance-determining region could be derived from two different clones. Based on gyrA and gyrB polymorphisms, C. jejuni isolates from the Dakar region of Senegal appeared to be less diverse than those from other countries. Moreover, C. jejuni isolates in Senegal appeared to differ from European isolates by lack of a silent mutation at codon 120 of the gyrA gene.
authors.affiliation: Laboratoire de Biologie Médicale, Institut Pasteur de Dakar, Senegal. kinana@pasteur.sn
authors.forename: Alfred Dieudonné
authors.initials: AD
authors.lastname: Kinana
authors.forename: Eric
authors.initials: E
authors.lastname: Cardinale
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Bahsoun
authors.forename: Fatou
authors.initials: F
authors.lastname: Tall
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Sire
authors.forename: Benoit
authors.initials: B
authors.lastname: Garin
authors.forename: Cheikh Saad-Bouh
authors.initials: CS
authors.lastname: Boye
authors.forename: Jacques-Albert
authors.initials: JA
authors.lastname: Dromigny
authors.forename: Jean-David
authors.initials: JD
authors.lastname: Perrier-Gros-Claude
mesh_terms: D000818:Animals; D002169:Campylobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016123:Campylobacter jejuni / Q000187:drug effects* / Q000235:genetics*; D027081:DNA Gyrase / Q000187:drug effects / Q000235:genetics*; D027101:DNA Topoisomerase IV / Q000187:drug effects / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D005060:Europe; D024841:Fluoroquinolones / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009268:Nalidixic Acid / Q000494:pharmacology; D011110:Polymorphism, Genetic; D012675:Senegal / Q000453:epidemiology
chemical_list: D024841:Fluoroquinolones; D009268:Nalidixic Acid; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase